TECH:NASDAQ
BIO-TECHNE Corp
$72.67
arrow_upward
+0.01%(+0.0100) 1D
$72.72
arrow_upward
+0.07% (+0.050)bedtimeAfter hours
Closed: Nov 2, 4:00:00 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for TECH...
Open
$72.67
High
$72.73
Low
$72.66
Mkt. cap
11.41B
Avg. vol.
2.92M
Volume
2.02M
Dividend
0.44%
Quarterly dividend
$0.08
Ex-dividend date
Aug 24, 2026
P/E ratio
62.75
52-wk high
$72.75
52-wk low
$43.20
EPS
$1.16
Beta
1.30
Shares outstanding
157.06M
No. of employees
3K
Open
$72.67
High
$72.73
Low
$72.66
Mkt. cap
11.41B
Avg. vol.
2.92M
Volume
2.02M
Dividend
0.44%
Quarterly dividend
$0.08
Ex-dividend date
Aug 24, 2026
P/E ratio
62.75
52-wk high
$72.75
52-wk low
$43.20
EPS
$1.16
Beta
1.30
Shares outstanding
157.06M
No. of employees
3K
News stories
From web sources and news partners
Investing.com
·
9 hours ago
Bio-Techne faces earnings test ahead of Merck acquisition close
Zacks
·
13 hours ago
Bio-Techne's Q1 Earnings on Deck: What's in Store for the Stock?
Yahoo Finance
·
14 hours ago
Bio-Techne's Q1 Earnings on Deck: What's in Store for the Stock?
Profile
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets. Wikipedia
About BIO-TECHNE Corp
CEOKim Kelderman
Employees3K
Founded1976
HeadquartersMinneapolis, Minnesota, United States
SectorHealth care
Websitebio-techne.com
Analyst ratings
Based on 3 analysts giving stock ratings to TECH in the past 3 months
Sell
Buy
0
Hold
2
Sell
1
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for TECH in the last 3 months.
Highest
Current $72.67
$73.00 (+0.45%)
Average
$73.00 (+0.45%)
Lowest
$73.00 (+0.45%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
David Toung Argus Research | Sell | Downgraded | - | - | 10/26/2026 |
Evan Stampler Wells Fargo | Hold | Downgraded | $73.00 | +0.5% | 08/14/2026 |
Dan Leonard RBC Capital | Hold | Maintained | $73.00 | +0.5% | 08/12/2026 |
Matt Larew William Blair | Hold | Reiterated | - | - | 08/12/2026 |
Kyle Boucher TD Cowen | Hold | Downgraded | $73.00 | +0.5% | 06/30/2026 |
Robert Wasserman StoneX | Hold | Downgraded | - | - | 06/30/2026 |
Patrick B Donnelly Citi | Hold | Downgraded | $73.00 | +0.5% | 06/29/2026 |
Steven Etoch Stephens | Hold | Downgraded | $73.00 | +0.5% | 06/26/2026 |
Catherine Ramsey Schulte Robert W. Baird | Hold | Maintained | $73.00 | +0.5% | 06/26/2026 |
Justin Bowers Deutsche Bank | Hold | Downgraded | $73.00 | +0.5% | 06/26/2026 |
Brandon Couillard Wells Fargo | Buy | Maintained | $62.00 | -14.7% | 06/26/2026 |
Puneet Souda Leerink Partners | Hold | Downgraded | $73.00 | +0.5% | 06/25/2026 |
David Westenberg Piper Sandler | Hold | Initiated | $65.00 | -10.6% | 06/11/2026 |
Unknown Analyst RBC Capital | Buy | Initiated | $62.00 | -14.7% | 05/14/2026 |
Daniel Arias Stifel Nicolaus | Hold | Maintained | $50.00 | -31.2% | 05/07/2026 |
Daniel Markowitz CFA Evercore ISI | Hold | Reiterated | $50.00 | -31.2% | 05/07/2026 |
Paul Knight KeyBanc | Hold | Maintained | - | - | 05/07/2026 |
Next call in 8 days
Wed, Nov 11, 9:00 AM
Fiscal period
Q1 2027
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
- / $0.45
Revenue / Est. (USD)
- / 292.20M
Fiscal Q1 2027 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 286.56M | 295.88M | 311.42M | 321.19M |
Cost of goods sold | 96.36M | 102.69M | 101.98M | 109.14M |
Cost of revenue | 96.36M | 102.69M | 101.98M | 109.14M |
Research and development expenses | 24.24M | 23.12M | 23.46M | 23.94M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 117.57M | 111.87M | 107.54M | 98.59M |
Operating expense | 141.81M | 134.99M | 130.99M | 122.53M |
Total operating expenses | 238.18M | 237.68M | 232.97M | 231.67M |
Operating income | 48.38M | 58.20M | 78.45M | 89.52M |
Other non operating income | 2.00M | -2.51M | -2.11M | 1.89M |
EBT including unusual items | 47.99M | 50.78M | 71.22M | 70.68M |
EBT excluding unusual items | 48.71M | 54.52M | 74.18M | 91.79M |
Income tax expense | 9.81M | 12.78M | 20.18M | 16.06M |
Effective tax rate | 20.43% | 25.16% | 28.33% | 22.72% |
Other operating expenses | - | - | - | - |
Net income | 38.18M | 38.01M | 51.05M | 54.62M |
Net profit margin | 13.33% | 12.85% | 16.39% | 17.01% |
Earnings per share | 0.42 | 0.46 | 0.53 | 0.52 |
Interest and investment income | 971.00K | 897.00K | 981.00K | 1.37M |
Interest expense | -2.93M | -2.17M | -2.40M | -2.12M |
Net interest expenses | -1.96M | -1.27M | -1.42M | -750.00K |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 72.72M | 82.91M | 102.62M | 113.66M |
Gain or loss from assets sale | -6.79M | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events